FDA reviews Pfizer's Xeljanz for RA; Isis sub Akcea wins orphan designation;

@FierceBiotech: Analyst Schoenebaum offers best-case scenario for Axovant's 4-time Alzheimer's loser. More | Follow @FierceBiotech

@JohnCFierce: The dog that didn't bark? Odd that $AXON trolls haven't been on my tail. Where are the die-hard fanatics? Is this mostly an insiders' game? | Follow @JohnCFierce

> The FDA has agreed to review Pfizer's ($PFE) once-daily formulation of Xeljanz for rheumatoid arthritis. Release

> Boston-based Akcea Therapeutics, a subsidiary of Isis ($ISIS), has received an orphan drug designation for volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with rare cases of Familial Chylomicronemia Syndrome. Release

Medical Device News

@FierceMedDev: ICYMI: Quest and Quintiles rev up new lab testing JV. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Greek referendum: Next big deadline is payment to ECB (assuming no bank run). Sad & ironic that technocrats still have to make this decision. | Follow @VarunSaxena2

@EmilyWFierce: A Perfect Blood Test For Pancreatic Cancer? Forbes story | Follow @EmilyWFierce

> Report: Despite growth in the device industry, effective concussion treatment remains elusive. More

> Allergan to buy dry eye device startup Oculeve for $125M+. News

Pharma News

@FiercePharma: USDA amends rules to allow vets to make custom vaccines in their offices. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Bayer draws up big sales plans for ex-Merck OTC meds. Story | Follow @CarlyHFierce

> Hospira's Remicade biosimilar wins large French contract with deep discount. More

> Sanofi and Gilead set sail to Japan with new approvals for Toujeo, Harvoni. Article

Pharma Marketing News

> Hot summer ad wars: Celgene launches Otezla DTC into crowded psoriasis drug market. More

> Sanofi, Regeneron break out the popcorn for cholesterol-fighting, PCSK9-friendly documentary. Story

> Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Article

> Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach. Item

> Hotel workers lobby to stop Big Pharma funding for CME. More

Animal Health News

> Flu season over? Not for dogs. Item

> Patterson offloads medical unit to private equity firm for $715M, boosts focus on animal health. Report

> Report: With Valeant takeover rumors fading, could Zoetis buy IDEXX? More

> USDA amends rules to allow vets to make custom vaccines in their offices. Story

> FDA, Gates Foundation call for improved global access to veterinary drugs. Article

Biotech IT News

> Broad Institute snaps up GemCode Platform as 10X Genomics starts shipping. News

> Novartis steps into wearables with app for Apple Watch, Android Wear. More

> Mousera bags $20M VC round to advance sensor tech in preclinical research. Story

> BioClinica mounts European expansion to push imaging and eClinical. Article

> Congressman pushes to unshackle pharma on social media. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.